Mark J. Fitzpatrick

Mark J.
Fitzpatrick currently works at Versantis AG, as Chief Executive Officer & Director from 2021 and Allena Pharmaceuticals, Inc., as Independent Director from 2021.
Mr. Fitzpatrick also formerly worked at Repligen Corp., as Principal, Diacrin, Inc. (Delaware), as Chief Financial Officer & Vice President from 1991 to 1998, Dynogen Pharmaceuticals, Inc., as Chief Financial Officer from 1998 to 2009, Proteon Therapeutics, Inc., as Chief Financial Officer & Vice President from 2007 to 2011, Aegerion Pharmaceuticals, Inc., as Chief Financial Officer from 2011 to 2015, Chiasma, Inc., as President & Chief Financial Officer from 2019 to 2021, RenaMed Biologics, Inc., as Chief Financial Officer, WorldStreet Corp., as Chief Financial Officer & Senior Vice President from 1998 to 2002, and Arthur Andersen LLP, as Senior Auditor.
Mr. Fitzpatrick received his undergraduate degree in 1984 from Boston College.